<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784420</url>
  </required_header>
  <id_info>
    <org_study_id>A5271019</org_study_id>
    <nct_id>NCT00784420</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study Between Raltegravir And UK-453,061</brief_title>
  <official_title>Open-Label, Randomized, 3-Way Crossover Study To Estimate The Interaction Between Multiple Dose Raltegravir And UK-453,061 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the effect of steady state raltegravir on the steady
      state pharmacokinetics of UK-453,061 and steady state UK-453,061 on the steady state
      pharmacokinetics of raltegravir.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Raltegravir plasma pharmacokinetic parameters: Cmax and AUC12</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>UK-453,061 plasma pharmacokinetic parameters: Cmax and AUC24</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Raltegravir plasma pharmacokinetic parameters: Tmax, t1/2, AUCinf, and C12h</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toleration assessed by spontaneous reporting of adverse events, vital signs, 12-lead ECG and laboratory safety assessments</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UK-453,061 plasma pharmacokinetic parameters: Tmax, t1/2, AUCinf, and C24h</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>UK-453,061</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>UK-453,061 plus Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UK-453,061</intervention_name>
    <description>UK-453,061 1000 mg once daily for 10 days</description>
    <arm_group_label>UK-453,061 plus Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UK-453,061</intervention_name>
    <description>UK-453,061 1000 mg once daily for 10 days</description>
    <arm_group_label>UK-453,061</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir 400 mg twice daily for 10 days</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir 400 mg twice daily for 10 days</description>
    <arm_group_label>UK-453,061 plus Raltegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive; Body
        Mass Index (BMI) of 18 to 30 kg/m2; and a total body weight &gt;50 kg (110 lbs). A BMI lower
        limit of 17.5 kg/m2 may be rounded up to 18.0 kg/m2; a BMI upper limit of 30.5 kg/m2 may be
        rounded down to 30.0 kg/m2 and will be acceptable for inclusion.

        Exclusion Criteria:

        Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,
        gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease;
        Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer)
        preceding the first dose of study medication; Use of tobacco- or nicotine-containing
        products in excess of the equivalent of 5 cigarettes per day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511-5473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5271019&amp;StudyName=Drug%20Interaction%20Study%20Between%20Raltegravir%20And%20UK-453%2C061</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2008</study_first_posted>
  <last_update_submitted>November 17, 2008</last_update_submitted>
  <last_update_submitted_qc>November 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Drug Interaction, Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

